Timing note: West Pharmaceutical Services says it will release results before the market opens on Thursday, July 23, 2026, followed by its call at 8:00 a.m. ET. Based on the current date, the report is today, July 23—not tomorrow.
West enters the quarter with strong fundamental momentum but an unusually high bar. First-quarter results materially exceeded expectations, prompting management to raise full-year guidance. Since that April 23 report, the shares have risen approximately 16%, closing July 22 at $358.45.
The complication is that West disclosed a significant cyberattack on May 4—after issuing its Q2 outlook. The upcoming report will therefore be less about whether underlying injectable-drug demand remains healthy and more about:
At the July 22 close, WST trades at approximately 42 times the midpoint of current 2026 adjusted EPS guidance. A routine beat may not be enough; investors will likely want evidence that the cyber event caused only temporary disruption and that the business can continue compounding beyond the unusually strong first quarter.
These are management’s April 23 targets, issued before the May cyberattack:
| Metric | Q2 2026 guidance | Implied year-over-year growth |
|---|---|---|
| Revenue | $830M–$850M | 8.3%–10.9% reported |
| Organic revenue growth | — | 7.0%–9.6% |
| Adjusted diluted EPS | $2.05–$2.12 | 11.4%–15.2% |
Management also indicated that Q2 adjusted operating margin should be approximately consistent with Q1’s 21.4%.
| Metric | 2026 guidance |
|---|---|
| Revenue | $3.295B–$3.350B |
| Organic growth | 7%–9% |
| Adjusted EPS | $8.40–$8.75 |
| Capital expenditures | $250M–$275M |
| Net interest income | Approximately $7M |
| Tax rate | Approximately 19% |
| Diluted shares | Approximately 71.5M |
For context, Q1 revenue was $844.9 million, organic growth was 15.3%, adjusted operating margin was 21.4%, and adjusted EPS was $2.13.
West detected a network intrusion on May 4, 2026 and shut down or isolated affected on-premise infrastructure. In its last formal update, dated May 11, the company said the incident had temporarily disrupted global operations. Core enterprise systems had been restored, and shipping, receiving and manufacturing had restarted at some sites, with restoration of the remaining sites still underway. At that point, West had not established a timeline for complete restoration.
This matters because the disruption began early in the second month of the quarter, while the Q2 guidance was set on April 23. The report should provide the first meaningful financial assessment.
Investors should separate three potential effects:
The most constructive outcome would be modest delayed revenue, limited permanent customer impact and largely completed remediation. A more concerning result would involve extended production constraints, lost orders, customer qualification concerns or a continuing lack of visibility.
Management’s ability to reaffirm full-year guidance despite the incident will probably matter more than the precise Q2 EPS result.
HVP components accounted for approximately 48% of Q1 company sales and grew 22.6% organically. This business is central to both revenue growth and margin expansion.
The strongest feature of Q1 was arguably not GLP-1 exposure but the acceleration in the rest of the HVP portfolio:
Management raised its 2026 expectation for non-GLP-1 HVP components to low-double-digit growth, representing just over five percentage points of total company growth at the midpoint.
For Q2, investors should look for evidence that this was durable end-market demand rather than a one-quarter capacity or order-timing benefit. Continued double-digit non-GLP-1 growth would broaden the investment case beyond obesity drugs.
GLP-1 HVP components represented approximately 10% of total company sales in Q1. Management expects this business to grow in the mid- to high teens in 2026.
Important questions include:
The market already recognizes WST as an indirect GLP-1 beneficiary, so merely reiterating the long-term opportunity may have limited impact. Actual growth and capacity execution will matter more.
West expects Annex 1-related conversions and broader HVP upgrades to contribute approximately two percentage points to 2026 growth. The number of related customer projects was up 66% year over year in Q1, and management has identified at least six billion units that could potentially be upgraded.
These conversions are particularly valuable because they can increase selling price and margin without requiring corresponding growth in drug-unit volumes. Investors should listen for:
West’s Q1 adjusted operating margin expanded 350 basis points to 21.4%, helped by favorable HVP mix, pricing, improved plant utilization and operating leverage.
Management previously suggested:
The cyberattack adds a new variable. Investors should distinguish between temporary incident-related expenses and any deterioration in underlying manufacturing economics.
A result near the revenue target but with weak margin or reduced second-half margin expectations would be disappointing. Conversely, holding operating margin near 21% despite the disruption would demonstrate substantial earnings resilience.
Q1 HVP delivery-device revenue rose 27.5% organically, partly because customers requested additional SmartDose 3.5 product ahead of the planned transaction. SmartDose strength was volume-driven and contributed to the unusually strong first-quarter result.
West had expected the transaction to close around midyear. Investors need clarity on:
Because accelerated SmartDose ordering benefited Q1, investors should avoid extrapolating total delivery-device growth without separating the retained portfolio.
West Vantage, formerly Contract Manufacturing, grew 6.2% organically in Q1. However, a continuous-glucose-monitoring contract was scheduled to end in Q2, creating an approximately $40 million second-half revenue headwind. Management previously identified Q3 as the likely low point.
The offset is West’s newer drug-handling business:
The key issue is whether drug handling is ramping quickly enough to make the CGM exit a temporary revenue transition rather than a longer-lasting earnings drag.
At current guidance midpoints, West would generate approximately:
That translates to average second-half quarterly revenue of roughly $819 million and adjusted EPS of approximately $2.18. The model therefore assumes lower average revenue than in the first half but improving earnings, supported by richer HVP mix, operational efficiency and the exit of lower-margin activities.
Bullish
Acceptable/base case
Bearish
CEO Eric Green has announced his intention to retire once a successor is appointed. Management previously expected an appointment during the second half of 2026.
Given the company’s operational momentum and premium valuation, investors will want a credible succession timeline and confidence that the next CEO will maintain West’s focus on HVP growth, capacity utilization and disciplined capital investment.
West authorized a new $1 billion repurchase program and bought back 1.2 million shares for approximately $298 million in Q1. With the stock now materially higher, investors should assess the pace of further repurchases and whether management prioritizes capacity investment, M&A or buybacks.
On July 14, West renewed its technology-sharing, cross-licensing and distribution agreements with Daikyo Seiko for another ten years. West retains a 49% stake in Daikyo and remains its exclusive distributor outside Japan, subject to limited exceptions.
This is strategically positive for West’s high-end containment and delivery portfolio, although it is unlikely to be a material near-term earnings catalyst.
The underlying business entered Q2 in excellent condition. Demand for biologics, GLP-1 components, NovaPure and Annex 1 upgrades was strong, while improved manufacturing execution was driving meaningful margin expansion.
But the stock already reflects much of that strength. At approximately 42 times the midpoint of 2026 adjusted EPS guidance and after a roughly 30% year-to-date gain, the burden of proof is higher.
The most important signal will not be the headline Q2 EPS figure in isolation. It will be whether management can demonstrate that the May cyberattack caused a temporary timing issue rather than a structural operating problem, while maintaining full-year guidance and confidence in second-half margin expansion. A guidance reaffirmation accompanied by clear evidence of normalized operations would likely preserve the growth thesis; an outlook cut or continuing uncertainty around production and customers would challenge the stock’s premium valuation.